Bleeding risk with trastuzumab (Herceptin) treatment.
Nissenblatt
M J
MJ
Karp
G I
GI
D000368:Aged; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000925:Anticoagulants / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy*; D004347:Drug Interactions; D005260:Female; D006801:Humans; D007020:Hypoprothrombinemias / Q000139:chemically induced*; D019934:International Normalized Ratio; D008875:Middle Aged; D000068878:Trastuzumab; D014859:Warfarin / Q000627:therapeutic use
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000925:Anticoagulants; D000970:Antineoplastic Agents; D014859:Warfarin; D000068878:Trastuzumab